Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
2019; National Comprehensive Cancer; Volume: 17; Issue: 5 Linguagem: Inglês
10.6004/jnccn.2019.0023
ISSN1540-1413
AutoresJames L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya B. Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric M. Horwitz, Michael E. Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael Kuettel, Joshua M. Lang, Jesse K. McKenney, George J. Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow‐Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach, Stan Rosenfeld, Edward M. Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan D. Tward, Dorothy A. Shead, Deborah A. Freedman-Cass,
Tópico(s)Genetic factors in colorectal cancer
ResumoThe NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.
Referência(s)